Adial Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Adial Pharmaceuticals de 6.2% y 94% respectivamente, mientras que el BPA crecerá en un 50.5% al año.

Información clave

6.2%

Tasa de crecimiento de los beneficios

50.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	94.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	21 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Adial Clinical Trial: A Fluff Or A Win?

Aug 22

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Aug 16

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Jun 21

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Jan 11

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Nov 25

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ADIL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-16	N/A	N/A	2
12/31/2025	N/A	-9	N/A	N/A	3
12/31/2024	N/A	-13	N/A	N/A	3
9/30/2024	N/A	-13	-7	-7	N/A
6/30/2024	N/A	-12	-6	-6	N/A
3/31/2024	N/A	-11	-6	-6	N/A
12/31/2023	N/A	-7	-7	-7	N/A
9/30/2023	N/A	-8	-7	-7	N/A
6/30/2023	N/A	-9	-9	-9	N/A
3/31/2023	N/A	-10	-11	-11	N/A
12/31/2022	N/A	-11	-11	-11	N/A
9/30/2022	N/A	-14	-12	-12	N/A
6/30/2022	N/A	-16	-12	-12	N/A
3/31/2022	N/A	-17	-12	-12	N/A
12/31/2021	N/A	-19	-12	-12	N/A
9/30/2021	N/A	-17	-12	-12	N/A
6/30/2021	N/A	-16	-11	-11	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-11	-8	-8	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-8	-6	-6	N/A
3/31/2020	N/A	-8	-6	-6	N/A
12/31/2019	N/A	-9	-6	-6	N/A
9/30/2019	N/A	-8	-6	-6	N/A
6/30/2019	N/A	-14	-5	-5	N/A
3/31/2019	N/A	-14	-4	-4	N/A
12/31/2018	N/A	-12	-2	-2	N/A
9/30/2018	N/A	-11	-2	-2	N/A
6/30/2018	N/A	-3	N/A	-1	N/A
3/31/2018	N/A	-1	N/A	-1	N/A
12/31/2017	N/A	-1	N/A	0	N/A
9/30/2017	N/A	-1	N/A	0	N/A
6/30/2017	N/A	-1	N/A	0	N/A
3/31/2017	N/A	0	N/A	0	N/A
12/31/2016	N/A	0	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ADIL siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ADIL siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ADIL siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ADIL no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ADIL no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ADIL se prevé que sea elevada dentro de 3 años.

Adial Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 19% to US$21.00

Price target decreased by 17% to US$17.00

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target increased to US$10.67

Forecast breakeven pushed back to 2024

Recent updates

Adial Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Genetic Diagnostic for Addiction Treatment

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 12, 2024

Adial Pharmaceuticals, Inc. Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

New major risk - Financial position

Adial Pharmaceuticals, Inc. Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend Ip Exclusivity on Core Technology to 2044

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $4.28365 million.

Adial Pharmaceuticals, Inc Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Adial Pharmaceuticals, Inc. announced that it has received $0.2875 million in funding

Price target decreased by 19% to US$21.00

New major risk - Share price stability

Price target decreased by 17% to US$17.00

Adial Pharmaceuticals, Inc. Appoints Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Adial Pharmaceuticals, Inc. announced delayed amended 10-Q filing

Adial Pharmaceuticals, Inc. announced that it has received $4.000001 million in funding

Adial Pharmaceuticals, Inc. announced that it expects to receive $4.000001 million in funding

Adial Pharmaceuticals Receives Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Adial Pharmaceuticals, Inc., Annual General Meeting, Nov 02, 2023

Adial Pharmaceuticals, Inc. Announces Board Changes

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Adial Pharmaceuticals, Inc. announced delayed 10-Q filing

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public Float

New major risk - Share price stability

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Compliance with Nasdaq Listing Rule 5550(b)(1)

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Adial Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Adial Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

Adial Pharmaceuticals, Inc. Announces Executive Changes

Adial Clinical Trial: A Fluff Or A Win?

Adial Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01

Adial Pharmaceuticals, Inc. Announces Topline Results For Onward Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder

Adial Pharmaceuticals Announces Database Lock for the ONWARD(TM) Phase 3 Clinical Trial

Price target increased to US$10.67

Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04

Independent Director recently bought US$67k worth of stock

Adial Pharmaceuticals, Inc. announced that it has received $0.8 million in funding from Bespoke Growth Partners, Inc.

Chairman recently bought US$55k worth of stock

Adial Pharmaceuticals, Inc. Announces Positive Pre-Clinical Data for PNV2 as A Drug Candidate for Triple Negative Breast Cancer

Director William Stilley has joined 3rd company board

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. Reaches Full Enrollment Target for ONWARD Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder

Adial Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding from Bespoke Growth Partners, Inc., Keystone Capital Partners LLC

Adial Pharmaceuticals Provides Regulatory and Development Update

Adial Pharmaceuticals, Inc. Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test

Revisiting Adial Pharmaceuticals: EMA Approval For Alcohol Use Disorder Pill Is A Critical Catalyst

Adial Pharmaceuticals, Inc. announced that it has received $2.100003 million in funding from Keystone Capital Partners LLC, Bespoke Growth Partners, Inc., Rountop Limited Partnership, LLP and another investor

Forecast breakeven pushed back to 2024

Adial Pharmaceuticals Achieves 50% Enrollment in landmark ONWARD™ Phase 3 Trial

Adial Pharmaceuticals, Inc. to File Fast Track Application for Ad04 with the FDA

New 90-day high: US$3.19

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) completed the acquisition of Purnovate, LLC from the members of Purnovate.

New 90-day high: US$2.34

Adial Pharmaceuticals shares +5% on receiving third patent for opioid use disorder candidate

Adial Pharmaceuticals, Inc. (NasdaqCM:ADIL) entered into an Equity Purchase Agreement to acquire Purnovate, LLC from the members of Purnovate.

Adial Pharmaceuticals, Inc. Announces Management and Board Changes, Effective December 14, 2020

Adial Pharmaceuticals, Inc. announced that it expects to receive funding from Keystone Capital Partners LLC

Adial Pharmaceuticals inks stock purchase agreement with Keystone Capital

Adial Pharmaceuticals, Inc. Announces That U.S. Food and Drug Administration Issues an Emergency Use Authorization for the Assure/Fastep® Covid-19 Igg/Igm Rapid Test Device

Adial Pharmaceuticals, Inc. Files for Expedited Review of AD04 with the FDA

Adial Pharmaceuticals, Inc. announced that it has received $0.5 million in funding from Bespoke Growth Partners, Inc.